In: Aura Biosciences

Aura Biosciences is trading on the Nasdaq Global Market
04/11/2021

Columbus Venture Partners Portfolio Company, Aura Biosciences, is trading on the Nasdaq Global Market Aura Biosciences (Cambridge, USA), whose founder is... Read More
Columbus close its third Investment Biotech Fund with 120€M
26/04/2021

 Read complete article here Read More
Aura Biosciences Announces Oversubscribed $80 Million Financing
22/03/2021

CAMBRIDGE, March 2021 -- Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for... Read More
Aura Biosciences Appoints David Johnson to Its Board of Directors
05/01/2021

CAMBRIDGE, Mass.--Aura Biosciences, a clinical-stage oncology company developing a novel class of drug conjugate therapies for multiple oncology indications, today announced... Read More
Aura Biosciences presents updated clinical data for AU-011
25/02/2020

Aura Biosciences presents updated phase 1b/2 clinical data for AU-011 at the 43rd Annual Macula Society Meeting Light-Activated AU-011 Holds Significant... Read More
Aura Biosciences Appoints George Golumbeski, Ph.D., as Chairman of the BOD
07/01/2020

Aura Biosciences Appoints George Golumbeski, Ph.D., as Chairman of the Board of Directors   CAMBRIDGE, Mass.-- Aura Biosciences, a clinical-stage biopharmaceutical... Read More
Aura Biosciences Announces Clinical Data at AAO 2019 Annual Meeting
02/10/2019

Aura Biosciences Announces Clinical Data Presentations at the Upcoming American Academy of Ophthalmology 2019 Annual Meeting   CAMBRIDGE, Mass.-- Aura Biosciences,... Read More
Aura Biosciences Completes $40 Million Series D Financing
02/04/2019

Aura announces the $40 million Series D round April 02, 2019.CAMBRIDGE, Mass.-Aura Biosciences, a leader in the development of novel targeted... Read More
Aura Biosciences presents Interim Phase 1b/2 Data at the ASRS Annual Meeting
26/07/2018

  Aura Biosciences Presents Interim Phase 1b/2 Data at the American Society of Retina Specialists (ASRS) Annual Meeting CAMBRIGE. USA. July... Read More
Aura Biosciences announces Update of Clinical Safety Efficacy
20/06/2018

  Aura Biosciences Announces Update of Clinical Safety and Efficacy Data on Lead Candidate AU-011 for Choroidal Melanoma CAMBRIGE. USA. June... Read More